Children’s Hospital and Genocea Biosciences partner

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Biotechs lag in social media use

MHT talks with Tanja Dominko, WPI researcher and CellThera president

MHT talks with Christopher Lambert of WPI Center for Neuroprosthetics

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

VBI Vaccines pulls in $2.2M debt round [February 13, 2012]

Zalicus, Hydra team up on pain treatment [February 10, 2012]

Ironwood stock offering aims for $80M [February 10, 2012]

Genocea Biosciences Inc. and Children’s Hospital Boston have announced an agreement under which Cambridge-based Genocea is licensing a portfolio of Streptococcus pneumoniae antigens developed in a collaboration among Genocea, Children’s and the Seattle-based research organization PATH.

Genocea, a vaccine discovery and development company, receives an exclusive worldwide license for developed countries to the antigens. PATH and Genocea retain certain co-exclusive rights to the antigens for use in developing countries. The antigens were identified through a 2008 research collaboration among the three organizations. The license grants Genocea the right to develop and commercialize vaccines that incorporate the antigens.

Genocea and Children’s Hospital said they have completed pre-clinical proof of concept studies on an S. pneumoniae vaccine developed using the antigens. The company and the group from Children’s Hospital are scheduled to present the results at the Seventh International Symposium on Pneumococci and Pneumococcal Diseases, ongoing this week in Tel Aviv.

S. pneumoniae, also known as pneumococcus, is a bacterium that can cause pneumonia, meningitis (brain infection and inflammation), acute otitis media (middle ear infections), bloodstream infections and sinus infections.

Genocea was founded in 2006 utilizing technology from the University of California at Berkeley and Harvard Medical School.
In December, Genocea was awarded a grant from the University of Pittsburgh Medical Center to develop vaccines to prevent the spread of chlamydia.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.